DE69632402D1 - 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste - Google Patents

4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste

Info

Publication number
DE69632402D1
DE69632402D1 DE69632402T DE69632402T DE69632402D1 DE 69632402 D1 DE69632402 D1 DE 69632402D1 DE 69632402 T DE69632402 T DE 69632402T DE 69632402 T DE69632402 T DE 69632402T DE 69632402 D1 DE69632402 D1 DE 69632402D1
Authority
DE
Germany
Prior art keywords
carboxamidoindole
aminiethyl
sulfonylharnstoffe
antagoniste
benzensulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69632402T
Other languages
English (en)
Other versions
DE69632402T2 (de
Inventor
E Hart
W Orme
M Moynihan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE69632402D1 publication Critical patent/DE69632402D1/de
Application granted granted Critical
Publication of DE69632402T2 publication Critical patent/DE69632402T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69632402T 1995-06-30 1996-05-29 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste Expired - Fee Related DE69632402T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74395P 1995-06-30 1995-06-30
US743 1995-06-30
PCT/US1996/007881 WO1997002036A1 (en) 1995-06-30 1996-05-29 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists

Publications (2)

Publication Number Publication Date
DE69632402D1 true DE69632402D1 (en) 2004-06-09
DE69632402T2 DE69632402T2 (de) 2005-05-19

Family

ID=21692834

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632402T Expired - Fee Related DE69632402T2 (de) 1995-06-30 1996-05-29 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste

Country Status (9)

Country Link
US (1) US5731326A (de)
EP (1) EP0835115B1 (de)
JP (1) JP3195363B2 (de)
AT (1) ATE265855T1 (de)
AU (1) AU5938696A (de)
DE (1) DE69632402T2 (de)
DK (1) DK0835115T3 (de)
ES (1) ES2217313T3 (de)
WO (1) WO1997002036A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
KR20040032115A (ko) * 2001-06-21 2004-04-14 베쓰 이스라엘 디코니스 메디칼 센터 인크 조직 및 장기 이식 결과의 개선 및 아폽토시스의 억제에사용되는 일산화탄소
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
EA200401070A1 (ru) * 2002-02-13 2005-02-24 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы лечения сосудистых заболеваний
US7687079B2 (en) * 2002-04-15 2010-03-30 University of Pittsburgh of the Commonwealth System of Higher Education Yale University Methods of treating ileus
UA86570C2 (ru) * 2002-04-15 2009-05-12 Юниверсити Оф Питтсбург Оф Дзе Коммонвелз Систем Оф Хайер Эдьюкейшн Способ лечения некротизирующего энтероколита
CA2482260A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Inc. Use of heme oxygenase-1 and products of heme degradation
ES2372273T3 (es) 2002-05-17 2012-01-17 Yale University Métodos de tratamiento de la hepatitis.
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
EA200500782A1 (ru) * 2002-11-07 2005-10-27 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Лечение геморрагического шока
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670700B2 (de) * 1966-05-14 1978-06-22 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
AU670937B2 (en) * 1992-04-28 1996-08-08 Wyeth Method of treating hyperproliferative vascular disease
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin

Also Published As

Publication number Publication date
US5731326A (en) 1998-03-24
EP0835115A1 (de) 1998-04-15
AU5938696A (en) 1997-02-05
DK0835115T3 (da) 2004-08-02
WO1997002036A1 (en) 1997-01-23
ATE265855T1 (de) 2004-05-15
DE69632402T2 (de) 2005-05-19
EP0835115B1 (de) 2004-05-06
JP2001502292A (ja) 2001-02-20
ES2217313T3 (es) 2004-11-01
JP3195363B2 (ja) 2001-08-06

Similar Documents

Publication Publication Date Title
DE69632402D1 (en) 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
CA2208673A1 (en) Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
AU6048396A (en) Use of brefeldin a and derivatives thereof in the treatment of hyperplasia and related disorders
GR3029354T3 (en) 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
BG103232A (en) Heterocyclic esters and amides
DE69024556T2 (de) Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
WO2000039280A8 (en) Leukocyte-derived interferon preparations
ATE253582T1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
ATE263187T1 (de) Neuartige heparin bindende peptide
ATE286536T1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
DE69413009T2 (de) Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
ATE201207T1 (de) Substituierte imidazo(4,5-b)pyridine und benzimidazole als angiotensin ii antagoniste
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
ITMI932468A0 (it) Nuovi difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
DE9307966U1 (de) Absturzstop als Fallsicherung für Schwingtore in Sport- und Mehrzweckhallen
WO1995030438A3 (en) Methods and compositions to enhance endogenous fibrinolytic activity
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.
KR940024274U (ko) 당구 큐대의 담부 손질 기구
IT1206319B (it) Dispositivo per lo scorrimento e l'ancoraggio di cassetti, cestelli corpi estraibili in genere, da mobili ed altro.
ITVI930073A1 (it) Cerniera registrabile per antine in luce di mobili
IT218761Z2 (it) Gruppo cerniera per il montaggio di ante e/o portelli di mobili in genere
ITFI930174A0 (it) Struttura modulare di mobile per la realizzazione in particolare ma non esclusivamente di armadi, cucine, espositori e similari.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee